About

Founded

2019

Headquarters

Klosterneuburg, Niederosterreich, Austria

Industry

Biotech

Company Description

Sarcura develops a machine platform for the large scale, industrial manufacturing of personalized cell therapies. Our target is to scale global manufacturing capacity for these life saving, patient specific cancer treatments from thousands of doses per year to hundreds of thousands, cost effective and safe for a all patients.

Quick Links

Website Jobs

Funding

Total Raised

9.6 million euros

Valuation

Undisclosed

Significant Investors

Hardware Club, Lansdowne Investment Company Cyprus, IST Cube, tecnet equity, Axilium Holding, Novacapital, Nina Capital

Company Traction

In February 2021, Sarcura partnered with imec to develop a silicon photonic-based cytometry solution allowing real-time process control and manipulation of cells.

Leadership Team

Daniela Buchmayr: Co-Founder & CEO of Sarcura. Former Group Director Innovation & Application Development at GEA Group.

Erwin Gorjup: Co-Founder & Director of Application Development of Sarcura. Former Programme Lead Cell Therapy at GEA Group.

‍Martin Fischlechner: Co-Founder & Director of Technical Development of Sarcura. Former Research Career Track Lecturer at the University of Southhampton.

Press

Tech.eu (November 19, 2022): Austria's Sarcura raises €7 million to bring "cutting-edge silicon" to cell therapy manufacturing

Sarcura